Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study-Reference-Cited by-同舟云学术

Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study

Published:2020-09-09 Issue:6 Volume:39 Page:2019-2028
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Ayele Henok Tadesse^ORCID,Reynier Pauline,Azoulay Laurent^ORCID,Platt Robert W.^ORCID,Cabaussel Josselin,Benayoun Serge,Filion Kristian B.^ORCID

Funder

Canadian Institutes of Health Research

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-020-03429-z.pdf

Reference30 articles.

1. Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36:403–415

2. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. 2011. (Accessed July 13, 2017, at https://www.fda.gov/drugs/drugsafety/ucm258314.htm.)

3. Santos DJ (2012) Benign prostatic hyperplasia: clinical manifestations and evaluation. TechVascIntervRadiol 15:265–269

4. Yuan JQ, Mao C, Wong SY et al (2015) Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore) 94:e974

5. McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in drug treatment of benign prostatic hyperplasia in Japan based on the National Database Open Data;International Journal of Urology;2024-09-02

2. Decoding the complexity of benign prostatic hyperplasia therapies in the PARTEM trial—authors’ reply;The Lancet Regional Health - Europe;2024-02

3. The Cardiovascular Safety of Five-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study;The American Journal of Medicine;2023-10

4. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial;The Lancet Regional Health - Europe;2023-08

5. Overview of current pharmacotherapeutic options in benign prostatic hyperplasia;Expert Opinion on Pharmacotherapy;2023-07-21